Allergy Immunotherapy Market to Surpass USD6.7B by 2031 as...

Allergy Immunotherapy Market to Surpass USD6.7B by 2031 as Biologics and SLIT Redefine Treatment

Postado 2025-04-17 13:01:31

275

[Hyderabad, April 17th, 2025]– The global Allergy Immunotherapy Market, valued at USD 2.9 billion in 2023, is projected to grow at a rate of 10.8% to reach USD 6.7 billion by 2031, reports ClearView Market Insights. Biologic breakthroughs and patient-friendly SLIT tablets are replacing temporary symptom relief.

Request Sample @ https://clearviewmarketinsights.com/report-details/global-allergy-immunotherapy-market/

2024 Industry Milestones

Biologics Revolution

Palforzia® becomes the first biologic for Mn allergy.
Viaskin™ Patch shows 88% efficacy in trials for milk allergy.

SLIT Dominance

Europe’s SLIT adherence hits 85%, doubling SCIT rates.
3 new FDA-fast-tracked SLIT tablets target pediatric allergies.

Personalised Medicine

mRNA Vaccines: ALK/Sanofi collaboration aims for 2027 launch.

Regional Leaders

North America (45%): Biologic adoption (Palforzia®, Xolair®).
Europe (XX%): SLIT tablet hub (Oralair®, Grastek®).
Asia-Pacific (XX%): Rising pollution allergies (12% CAGR).

Executive Insights
“We’re transitioning from treating symptoms to reprogramming immune responses.”
– Carsten Hellmann, CEO, ALK-Abelló

Roadmap to 2031

2025: SLIT to overtake SCIT in revenue.
2027: 50% of food allergy patients on biologics/patches.
2030: Asia-Pacific market to triple with urbanization.

For more insights, visit https://clearviewmarketinsights.com/report-store

About Clearview Market Insights:

Clearview Market Insights is a leading market research and consulting firm providing in-depth industry analysis and strategic recommendations for businesses worldwide.

Media contact:

Bhavani K

Marketing and Sales Head

ClearView Market Insights

Mail: sales@clearviewmarketinsights.com

Phone: +1 917-993-7369

Faça o login para curtir, compartilhar e comentar!

Patrocinado